Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. Here we show that a combination of monoclonal antibodies (ZMapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal haemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use.
Ebola virus (EBOV) infections cause severe illness in humans, and after an incubation period of 3 to 21 days, patients initially present with general flu-like symptoms before a rapid progression to advanced disease characterized by haemorrhage, multiple organ failure and a shock-like syndrome 1 . In the spring of 2014, a new EBOV variant emerged in the West African country of Guinea 2 , an area in which EBOV had not been previously reported. Despite a sustained international response from local and international authorities including the Ministry of Health (MOH), World Health Organization (WHO) and Médecins Sans Frontières (MSF) since March 2014, the outbreak has yet to be brought to an end after five months. As of 15 August 2014, there are 2,127 total cases and 1,145 deaths spanning Guinea, Sierra Leone, Liberia and Nigeria 3 . So far, this outbreak has set the record for the largest number of cases and fatalities, in addition to geographical spread 4 . Controlling an EBOV outbreak of this magnitude has proven to be a challenge and the outbreak is predicted to last for at least several more months 5 . In the absence of licensed vaccines and therapeutics against EBOV, there is little that can be done for infected patients outside of supportive care, which includes fluid replenishment, administration of antivirals, and management of secondary symptoms 6, 7 . With overburdened personnel, and strained local and international resources, experimental treatment options cannot be considered for compassionate use in an orderly fashion at the moment. However, moving promising strategies forward through the regulatory process of clinical development has never been more urgent.
Over the past decade, several experimental strategies have shown promise in treating EBOV-challenged nonhuman primates (NHPs) after infection. These include recombinant human activated protein C (rhAPC) 8 , recombinant nematode anticoagulant protein c2 (rNAPc2) 9 , small interfering RNA (siRNA) 10 , positively-charged phosphorodiamidate morpholino oligomers (PMOplus) 11 , the vesicular stomatitis virus vaccine (VSVDG-EBOVGP) 12 , as well as the monoclonal antibody (mAb) cocktails MB-003 (consisting of human or human-mouse chimaeric mAbs c13C6, h13F6 and c6D8) 13 and ZMAb (consisting of murine mAbs m1H3, m2G4 and m4G7) 14 . Of these, only the antibody-based candidates have demonstrated substantial benefits in NHPs when administered greater than 24 h past EBOV exposure. Follow-up studies have shown that MB-003 is partially efficacious when administered therapeutically after the detection of two disease 'triggers' 15 , and ZMAb combined with an adenovirus-based adjuvant provides full protection in rhesus macaques when given up to 72 h after infection 16 .
The current objective is to develop a therapeutic superior to both MB-003 and ZMAb, which could be used for outbreak patients, primary health-care providers, as well as high-containment laboratory workers in the future. This study aims to first identify an optimized antibody combination derived from MB-003 and ZMAb components, before determining the therapeutic limit of this mAb cocktail in a subsequent experiment. To extend the antibody half-life in humans and to facilitate clinical acceptance, the individual murine antibodies in ZMAb were first chimaerized with human constant regions (cZMAb; components: c1H3, c2G4 and c4G7). The cZMAb components were then produced in Nicotiana benthamiana 17 , using the large-scale, Current Good Manufacturing Practice-compatible Rapid Antibody Manufacturing Platform (RAMP) and magnICON vectors that currently also manufactures the individual components of cocktail MB-003, before efficacy testing in animals.
Selecting for the best mAb combinations
Our efforts to down-select for an improved mAb cocktail comprising components of MB-003 and ZMAb began with the testing of individual MB-003 antibodies in guinea pigs and NHPs. In guinea pig studies, animals were given one dose of mAb c13C6, h13F6 or c6D8 individually (totalling 5 mg per animal) at 1 day post-infection (dpi) with 1,000 3 LD 50 (median lethal dose) of guinea-pig-adapted EBOV, Mayinga variant (EBOV-M-GPA). Survival and weight loss were monitored over 28 days. Treatment with c13C6 or h13F6 yielded 17% survival (1 of 6 animals) with a mean time to death of 8.4 6 1.7 and 10.2 6 1.8 days, respectively. The average weight loss for c13C6 or h13F6-treated animals was 9% and 21% (Table 1 ). In nonhuman primates, animals were given three doses of mAb c13C6, h13F6 or c6D8, beginning at 24 h after challenge with the Kikwit variant of EBOV (EBOV-K) 18 , and survival was monitored over 28 days. Only c13C6 treatment yielded any survivors, with 1 of 3 animals protected from EBOV challenge (Table 1) , confirming in two separate animal models that c13C6 is the component that provides the highest level of protection in the MB-003 cocktail.
We then tested mAb c13C6 in combination with two of three mAbs from ZMAb in guinea pigs. The individual antibodies composing ZMAb were originally chosen for protection studies based on their in vivo protection of guinea pigs against EBOV-M-GPA 19 , and all three possible combinations were tested: ZMapp1 (c13C61c2G41c4G7), ZMapp2 (c13C61c1H31c2G4) and ZMapp3 (c13C61c1H31c4G7), and compared to the originator cocktails ZMAb and MB-003. Three days after 0  10  20  30  0  10  20  30   0  10  20  30  0  10  20  30  0  10  20  30   0  10  20  30  0  10  20  30  0  10  20  30   0  10  20  0  0  5  10 15 20 25 30  3 6 9 12 15 18 21 24 27 with ZMapp1 and ZMapp2. Rhesus macaques were challenged with EBOV-K, and 50 mg kg 21 of ZMapp1 (Group A) or ZMapp2 (Group B) were administered on days 3, 6, and 9 (n 5 6 per treatment group, n 5 2 for controls). Non-specific IgG mAb or PBS was administered as a control (Group C 
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challenge with 1,000 3 LD 50 of EBOV-M-GPA, the animals received a single combined dose of 5 mg of antibodies. This dosage is purposely given to elicit a suboptimal level of protection with the cZMAb and MB-003 cocktails, such that potential improvements with the optimized mAb combinations can be identified. Of the tested cocktails, ZMapp1 showed the best protection, with 4 of 6 survivors and less than 5% average weight loss (Table 1) . ZMapp2 was next with 3 of 6 survivors and 8% average weight loss, and ZMapp3 protected 1 of 6 animals ( Table 1 ). The level of protection afforded by ZMapp3 was not a statistically significant increase over cZMAb (P 5 0.224, log-rank test compared to ZMAb, x 2 5 1.479, degrees of freedom (d.f.) 5 1), and showed the same survival rate along with a similar average weight loss ( Table 1) . As a result, only ZMapp1 and ZMapp2 were carried forward to NHP studies.
ZMapp1 or ZMapp2-treated NHPs
Rhesus macaques were used to determine whether administration of ZMapp1 or ZMapp2 was superior to ZMAb and MB-003 in terms of extending the treatment window. Owing to mAb availability constraints, m4G7 was used in place of c4G7 for this NHP experiment. The experiment consisted of six NHPs per group receiving three doses of ZMapp1 (Group A) or ZMapp2 (Group B) at 50 mg kg 21 intravenously at 3-day intervals, beginning 3 days after a lethal intramuscular challenge with 4,000 3 median tissue culture infective dose (TCID 50 ) (or 2,512 plaqueforming units (p.f.u.)) of EBOV-K. Control animals were given phosphatebuffered saline (PBS) or mAb 4E10 (C1 and C2, respectively). Mock-treated animals succumbed to disease between 6-7 dpi with symptoms typical of EBOV ( Fig. 1a ), characterized by high clinical scores but no fever ( Fig. 1b, c ), in addition to viral titres up to approximately 10 8 and 10 9 TCID 50 by the time of death ( Fig. 1d ). Analysis of blood counts and serum biochemistry revealed leukocytopenia, thrombocytopenia, severe rash, decreased levels of glucose, as well as increased levels of alkaline phosphatase, alanine aminotransferase, blood urea nitrogen and creatinine at end-stage EBOV disease ( Fig. 1e -o, Table 2 ). All six Group A NHPs survived the challenge with mild signs of disease ( Fig. 1a , Table 2 ) (P 5 0.0039, log-rank test, x 2 5 8.333, d.f. 5 1, comparing to Group C), with the exception of A1 which showed an elevated clinical score ( Fig. 1b ), increased levels of alanine aminotransferase, total bilirubin, and decreased phosphate ( Fig. 1 , Table 2 ). However, this animal recovered after the third ZMapp1 dose and the clinical score dropped to zero by 15 dpi (Fig. 1b) . A fever was detected in all but one of the NHPs (A4) at 3 dpi, the start of the first ZMapp1 dose (Fig. 1c ). Viraemia was also detected beginning at 3 dpi by TCID 50 in all but one animal from blood sampled just before the administration of treatment (A3) (Fig. 1d ), and similar results were observed by quantitative PCR with reverse transcription (RT-qPCR, Extended Data Table 1 ). The viraemia decreased to undetectable levels by 21 dpi. EBOV shedding was not detected from oral, nasal and rectal swabs by RT-qPCR in any of the Group A animals (Extended Data Tables 2-4) .
For Group B, 5 of 6 NHPs survived with B3 succumbing to disease at 9 dpi ( Fig. 1a ) (P 5 0.0039, log-rank test, x 2 5 8.333, d.f. 5 1, comparing to Group C). Surviving animals showed only mild signs of disease ( Table 2 ). The moribund animal showed increased clinical scores ( Fig. 1b ), ALT""" (9 dpi), TBIL"" (9 dpi), BUN""" (9 dpi), CRE""" (9 dpi), GLU## (9 dpi) ALP" (3 dpi), ALT""" (6 dpi), BUN" (6 dpi), CRE""" (6 dpi)
Died, 6 dpi
Hypothermia was defined as below 35 uC. Fever was defined as .1.0 uC higher than baseline. Mild rash was defined as focal areas of petechiae covering ,10% of the skin, moderate rash as areas of petechiae covering 10 to 40% of the skin, and severe rash as areas of petechiae and/or ecchymosis covering .40% of the skin. Leukocytopenia and thrombocytopenia were defined as a .30% decrease in numbers of white blood cells and platelets, respectively. Leukocytosis and thrombocytosis were defined as a twofold or greater increase in numbers of white blood cells and platelets over baseline, where white blood cell count . 11 3 10 3 . ", two-to threefold increase; "", four-to fivefold increase; """, greater than fivefold increase; #, two-to threefold decrease; ##, four-to fivefold decrease; ###, greater than fivefold decrease. ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; TBIL, total bilirubin; BUN, blood urea nitrogen; PHOS, phosphate; CRE, creatinine; GLU, glucose; GLOB, globulin.
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in addition to a drastic drop in body temperature shortly before death ( Fig. 1c ). At the time of death, animal B3 had elevated levels of alanine aminotransferase, total bilirubin, blood urea nitrogen and creatinine, in addition to decreased levels of glucose, suggesting multiple organ failure ( Fig. 1 ). All six Group B animals showed fever in addition to viraemia at 3 dpi by TCID 50 and RT-qPCR ( Fig. 1d , Extended Data Table 1 ). It was interesting to note that in B3, the viraemia reached approximately 10 6 TCID 50 after 3 dpi ( Fig. 1d ), suggesting that this NHP was particularly susceptible to EBOV infection. No escape mutants were detected with this animal. The administration of ZMapp2 at the reported concentrations was unable to effectively control viraemia at this level. Virus shedding was also detected from the oral and rectal swabs by RT-qPCR in the moribund NHP B3 (Extended Data Tables 2-4 ). Since ZMapp1 demonstrated superior protection to ZMapp2 in this survival study, ZMapp1 (now trademarked as ZMapp by MappBio Pharmaceuticals) was carried forward to test the limits of protection conferred by this mAb cocktail in a subsequent investigation.
ZMapp-treated NHPs
In this experiment, rhesus macaques were assigned into three treatment groups of six and a control group of three animals, with all treatment NHPs receiving three doses of ZMapp (c13C61c2G41c4G7, 50 mg kg 21 per dose) spaced 3 days apart. After a lethal intramuscular challenge with 1,000 3 TCID 50 (or 628 p.f.u.) of EBOV-K 18 , we treated the animals with ZMapp at 3, 6 and 9 dpi (Group D); 4, 7, and 10 dpi (Group E); or 5, 8 and 11 dpi (Group F). The control animals (Group G) were given mAb 4E10 as an IgG isotype control (n 5 1) or PBS (n 5 2) in place of ZMapp starting at 4 dpi ( Fig. 2a ). All animals treated with ZMapp survived the infection, whereas the three control NHPs (G1, G2 and G3) succumbed to EBOV-K infection at 4, 8 and 8 dpi, respectively (P 5 3.58 3 10 25 , log-rank test, x 2 5 23.25, d.f. 5 3, comparing all groups) ( Fig. 2b) . At the time ZMapp treatment was initiated, fever, leukocytosis, thrombocytopenia and viraemia could be detected in the majority of the animals ( Fig. 2c-f , Table 3 , Extended Data Table 5 ). All animals presented with detectable abnormalities in blood counts and serum biochemistry during the course of the experiment (Fig. 2g-l , Table 3 ). The Group F animals did not seem to be as sick as animals E4 and E6 on the basis of clinical scores (Fig. 2c, Extended Data Fig. 1 ), both animals E4 and E6 were near the clinical limit for IACUC mandated euthanasia at 5 and 7 dpi, respectively. Animal E4 had a flushed face and severe rash on more than 40% of its body surface between 5 and 8 dpi in addition to nasal haemorrhage at 7 dpi, and animal E6 had a flushed face and petechiae on its arms and legs between 7 and 9 dpi, in addition to jaundice between 10 and 14 dpi. This indicates that host genetic factors may have a role in the differential susceptibility of individual NHPs to EBOV-K infections. Fever, leukocytosis, thrombocytopenia and a )  D1  D2  D3  D4  D5  D6  E1  E2  E3  E4  E5  E6  F1  F2  F3  F4  F5  F6  G1 G2 G3 ALP" (7, 10, 14 dpi), ALT """ (7 dpi), ALT "" (10 dpi), AMY# (4, 7, 10 dpi), TBIL""" (7 dpi), TBIL" (10, 14 dpi), PHOS# (7, 10 dpi), K 1 # (4 dpi) Survived E5 50 mg kg 21 ZMapp, 4 dpi Fever (7 dpi) Leukocytosis (4 dpi) Thrombocytopenia (4, 7, 10, 14 dpi)
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ALT" (7 dpi), AMY# (4, 7 dpi), PHOS# (10 dpi) Survived E6 50 mg kg 21 ZMapp, 4 dpi Fever (4 dpi) Mild rash (7, 8, 9 dpi) Leukocytosis (4, 10, 14 dpi) Thrombocytopenia (4, 7, 10, 14 dpi)
ALP" (7, 10 dpi), ALT """ (7, 10, 14 dpi), AMY# (7, 10 dpi), TBIL"" (7 dpi), TBIL""" (10 dpi), TBIL" (14 dpi), PHOS# (7 dpi), GLOB" (21 dpi) Survived F1 50 mg kg 21 ALP" (8 dpi), ALT" (7, 8 dpi), AMY# (7 dpi), AMY ## (8 dpi), TBIL" (8 dpi), PHOS# (7 dpi)
Died, 8 dpi
Hypothermia was defined as below 35 uC. Fever was defined as .1.0 uC higher than baseline. Mild rash was defined as focal areas of petechiae covering ,10% of the skin, moderate rash was defined as areas of petechiae covering 10 to 40% of the skin, and severe rash was defined as areas of petechiae and/or ecchymosis covering .40% of the skin. Leukocytopenia and thrombocytopenia were defined as a . 30% decrease in the numbers of white blood cells and platelets, respectively. Leukocytosis and thrombocytosis were defined as a twofold or greater increase in numbers of white blood cells and platelets above baseline, where white blood cell count . 11 3 10 3 . ", two-to threefold increase; "", four-to fivefold increase; """, greater than fivefold increase; #, two-to threefold decrease; ##, four-to fivefold decrease; ###, greater than fivefold decrease. ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; TBIL, total bilirubin; BUN, blood urea nitrogen; PHOS, phosphate; CRE, creatinine; GLU, glucose; K 1 , potassium; GLOB, globulin.
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severe rash symptomatic of EBOV disease progression were detected in both E4 and E6 (Table 3) . Increases in the level of liver enzymes alanine aminotransferase (10-to 30-fold increase), alkaline phosphatase (twoto threefold), and total bilirubin (3-to 11-fold) indicate significant liver damage ( Fig. 2g-l) , a hallmark of filovirus infections. However, ZMapp was successful in reversing observed disease symptoms and physiological abnormalities after 12 dpi, 2 days after the last ZMapp administration (Table 3) . Furthermore, ZMapp treatment was able to lower the high virus loads observed in animals F2 and F5 (up to 10 6 TCID 50 ml 21 ) to undetectable levels by 14 dpi (Fig. 2f, Extended Data Fig. 2) .
ZMapp cross-reacts with Guinea EBOV
Although the results were very promising with EBOV-K-infected NHPs, it was unknown whether therapy with ZMapp would be similarly effective against the Guinean variant of EBOV (EBOV-G), the virus responsible for the West African outbreak. Direct comparison of published amino acid sequences between EBOV-G and EBOV-K showed that the epitopes targeted by ZMapp 20, 21 were not mutated between the two virus variants (Fig. 3a) , indicating that the antibodies should retain their specificity for the viral glycoprotein. To confirm this, in vitro assays were carried out to compare the binding affinity of c13C6, c2G4 and c4G7 to sucrosepurified EBOV-G and EBOV-K. As measured by enzyme-linked immunosorbent assay (ELISA), the ZMapp components showed slightly better binding kinetics for EBOV-G than for EBOV-K (Fig. 3b) . Additionally, the neutralizing activity of individual mAbs was evaluated in the absence of complement for c2G4 and c4G7, and in the presence of complement for c13C6, as they have previously been shown to neutralize EBOV only under these conditions 13 (Fig. 3c) . The results supported the ELISA binding data, with comparable neutralizing activities between the two viruses.
Discussion
The West African outbreak of 2014 has highlighted the troubling absence of available vaccine or therapeutic options to save thousands of lives and stop the spread of EBOV. The lack of a clinically acceptable treatment offers limited incentive for people who suspect they might be infected to report themselves for medical help. Several previous studies have showed that antibodies are crucial for host survival from EBOV [22] [23] [24] . Prior NHP studies have also demonstrated that the ZMAb cocktail could protect 100% or 50% of animals when dosing was initiated 1 or 2 dpi, while the MB-003 cocktail protected 67% of animals with the same dosing regimen. Before the success with monoclonal-antibody-based therapies, other candidate therapeutics had only demonstrated efficacy when given within 60 min of EBOV exposure. Our results with ZMapp, a cocktail comprising of individual monoclonal antibodies selected from MB-003 and ZMAb, demonstrate for the first time the successful protection of NHPs from EBOV disease when intervention was initiated as late as 5 dpi. In the preceding ZMapp1/ ZMapp2 experiment, 11 out of 12 treated animals had detectable fever (with the exception of A4), and live virus could be detected in the blood of 11 out of 12 animals (with the exception of A3) by 3 dpi. Therefore, for the majority of these animals, treatment was therapeutic (as opposed to post-exposure prophylaxis), initiated after two detectable triggers of disease. ZMapp2 was able to protect 5 of 6 animals when administered at 3 dpi. For reasons currently unknown, the lone non-survivor (B3) experienced a viraemia of 10 6 TCID 50 at 3 dpi, which is 100-fold greater than all other NHPs and approximately tenfold higher than that which ZMAb has been reported to suppress in a previous study 16 . This indicates enhanced EBOV replication in this animal, possibly owing to host factors. It is important to note that, despite the high levels of live circulating virus detected in B3, ZMapp2 administration was still able to prolong the life of this animal to 9 dpi, and suggests that in cases of high viraemia such as this, the dosage of monoclonal antibodies should be increased.
The highlight of these experimental results is undoubtedly ZMapp, which was able to reverse severe EBOV disease as indicated by the elevated liver enzymes, mucosal haemorrhages and rash in animals E4 and E6. The high viraemia (up to 10 6 TCID 50 ml 21 of blood in some animals at the time of intervention) could also be effectively controlled without the presence of escape mutants, leading to full recovery of all treated NHPs by 28 dpi. In the absence of direct evidence demonstrating ZMapp efficacy against lethal EBOV-G infection in NHPs, results from ELISA and Guinea variants of EBOV, and in vitro antibody assays of mAbs c13C6, c2G4 and c4G7 with EBOV-G or EBOV-K virions. a, Sequence alignment of the EBOV glycoprotein from the Kikwit (EBOV-K) and Guinea (EBOV-G) variants, with the binding epitopes of ZMapp indicated with an arrow. b, ELISA, note that for each antibody, the median effective concentrations (EC 50 ) are different (P , 0.05, regression analysis) between the two antigens. c, Neutralizing antibody assay showing the activity of the individual mAbs composing ZMapp against EBOV-K (black) and EBOV-G (purple), the samples were run in triplicate.
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and neutralizing antibody assays show that binding specificity is not abrogated between EBOV-K and EBOV-G, and therefore the levels of protection should not be affected. The compassionate use of ZMapp in two infected American healthcare workers, with apparently positive results pertaining to survival and reversion of EBOV disease 25 , may support this assertion. Rhesus macaques have approximately 55-80 ml of blood per kg of body weight 26 ; at a dose of 50 mg kg 21 of antibodies, the estimated starting concentration is approximately 625-909 mg ml 21 of blood (total; ,200-300 mg ml 21 for each antibody). Therefore, the low median effective concentration (EC 50 ) values for EBOV-G (0.004-0.02 mg ml 21 ) bode well for treating EBOV-G infections with ZMapp.
Since the host antibody response is known to correlate with and is required for protection from EBOV infections 23, 24 , monoclonal-antibodybased treatments are likely to form the centrepiece of any future therapeutic strategies for fighting EBOV outbreaks. However, whether ZMapp-treated survivors can be susceptible to re-infection is unknown. In a previous study of murine ZMAb-treated, EBOV-challenged NHP survivors, a rechallenge of these animals with the same virus at 10 and 13 weeks after initial challenge yielded 6 of 6 survivors and 4 of 6 survivors, respectively 27 . While specific CD4 1 and CD8 1 T-cell responses could be detected in all animals, the circulating levels of glycoprotein (GP)-specific IgG were shown to be tenfold lower in non-survivors compared to survivors, suggesting that antibody levels may be indicative of protective immunity 27 . Sustained immunity with experimental EBOV vaccines in NHPs remains unknown; however, in a recent study, a decrease in GP-specific IgG levels due to old age or a suboptimal reaction to the VSVDG/EBOVGP vaccine in rodents also seem to be indicative of non-survival 28 .
ZMapp consists of a cocktail of highly purified monoclonal antibodies; which constitutes a less controversial alternative than whole-blood transfusions from convalescent survivors, as was performed during the 1995 EBOV outbreak in Kikwit 29 . The safety of monoclonal antibody therapy is well documented, with generally low rates of adverse reactions, the capacity to confer rapid and specific immunity in all populations, including the young, the elderly and the immunocompromised, and if necessary, the ability to provide higher-than-natural levels of immunity compared to vaccinations 30 . The evidence presented here suggests that ZMapp offers the best option of the experimental therapeutics currently in development for treating EBOV-infected patients. We hope that initial safety testing in humans will be undertaken soon, preferably within the next few months, to enable the compassionate use of ZMapp as soon as possible.
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